• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Pre-Market Session

    10/20/23 9:05:58 AM ET
    $AHG
    $AMWL
    $ARAV
    $ARQT
    Real Estate
    Real Estate
    Real Estate
    Real Estate
    Get the next $AHG alert in real time by email

    Gainers

    • Lipella Pharmaceuticals (NASDAQ:LIPO) stock increased by 43.5% to $2.31 during Friday's pre-market session. The company's market cap stands at $13.4 million.
    • Aravive (NASDAQ:ARAV) stock increased by 17.18% to $0.17. The company's market cap stands at $12.1 million.
    • American Well (NYSE:AMWL) stock rose 16.56% to $1.1. The company's market cap stands at $313.1 million.
    • Akso Health Group (NASDAQ:AHG) stock rose 11.99% to $1.4. The company's market cap stands at $32.0 million.
    • Comera Life Sciences (NASDAQ:CMRA) stock increased by 11.46% to $0.3. The market value of their outstanding shares is at $9.1 million.
    • 180 Life Sciences (NASDAQ:ATNF) shares increased by 11.24% to $0.5. The market value of their outstanding shares is at $2.9 million.

    Losers

    • Processa Pharma (NASDAQ:PCSA) stock fell 24.1% to $0.41 during Friday's pre-market session. The market value of their outstanding shares is at $10.0 million.
    • Arcutis Biotherapeutics (NASDAQ:ARQT) shares decreased by 19.48% to $2.44. The company's market cap stands at $150.4 million.
    • SeaStar Medical Holding (NASDAQ:ICU) shares fell 18.27% to $0.97. The market value of their outstanding shares is at $18.9 million.
    • Biocept (NASDAQ:BIOC) shares declined by 16.92% to $0.56. The market value of their outstanding shares is at $1.4 million.
    • Atreca (NASDAQ:BCEL) shares decreased by 16.49% to $0.31. The company's market cap stands at $12.0 million.
    • Meihua Intl Medical Techs (NASDAQ:MHUA) shares declined by 11.12% to $1.6. The market value of their outstanding shares is at $38.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AHG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AHG
    $AMWL
    $ARAV
    $ARQT

    CompanyDatePrice TargetRatingAnalyst
    Arcutis Biotherapeutics Inc.
    $ARQT
    7/25/2025$18.00Neutral
    Goldman
    American Well Corporation
    $AMWL
    1/13/2025$15.00Equal Weight → Overweight
    Wells Fargo
    Arcutis Biotherapeutics Inc.
    $ARQT
    12/30/2024$19.00Buy
    H.C. Wainwright
    Arcutis Biotherapeutics Inc.
    $ARQT
    8/28/2024$15.00Buy
    Jefferies
    Processa Pharmaceuticals Inc.
    $PCSA
    4/25/2024$8.00Buy
    H.C. Wainwright
    Arcutis Biotherapeutics Inc.
    $ARQT
    1/3/2024$4.00 → $8.00Neutral → Buy
    Mizuho
    Arcutis Biotherapeutics Inc.
    $ARQT
    10/26/2023$57.00 → $4.00Buy → Neutral
    Mizuho
    Arcutis Biotherapeutics Inc.
    $ARQT
    10/13/2023$32.00 → $6.00Buy → Neutral
    Goldman
    More analyst ratings

    $AHG
    $AMWL
    $ARAV
    $ARQT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on Arcutis Biotherapeutics with a new price target

    Goldman initiated coverage of Arcutis Biotherapeutics with a rating of Neutral and set a new price target of $18.00

    7/25/25 9:06:04 AM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amwell upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Amwell from Equal Weight to Overweight and set a new price target of $15.00

    1/13/25 7:29:38 AM ET
    $AMWL
    Real Estate

    H.C. Wainwright initiated coverage on Arcutis Biotherapeutics with a new price target

    H.C. Wainwright initiated coverage of Arcutis Biotherapeutics with a rating of Buy and set a new price target of $19.00

    12/30/24 7:23:09 AM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $AMWL
    $ARAV
    $ARQT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC

    Submission status for ARCUTIS BIOTHERAPEUTICS INC's drug ZORYVE (ORIG-1) with active ingredient ROFLUMILAST has changed to 'Approval' on 12/15/2023. Application Category: NDA, Application Number: 217242, Application Classification: Type 3 - New Dosage Form

    12/19/23 3:40:08 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC

    Submission status for ARCUTIS BIOTHERAPEUTICS INC's drug ZORYVE (ORIG-1) with active ingredient ROFLUMILAST has changed to 'Approval' on 12/15/2023. Application Category: NDA, Application Number: 217242, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    12/15/23 5:01:31 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $AMWL
    $ARAV
    $ARQT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Arcutis Management to Present at TD Cowen's 46th Annual Health Care Conference

    WESTLAKE VILLAGE, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will present at the TD Cowen 46th Annual Health Care Conference, taking place March 2-4, 2026, in Boston. Details for the Company's participation are as follows:     Fireside Chat: Monday, March 2, 2026 at 1:50 p.m. ET The webcast for this conference may be accessed via the "Events" section of the Company's website. A replay of the webcast will be available on the Arcutis website for 180 days following the conference. About ArcutisAr

    2/27/26 4:00:00 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Q4 2025 net product revenue for ZORYVE® (roflumilast) was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 2025Full year 2025 net product revenue for ZORYVE was $372.1 million, an increase of 123% over the prior yearReported positive topline data for the INTEGUMENT-INFANT Phase 2 trial of ZORYVE cream 0.05% in children ages 3 to 24 months with mild to moderate atopic dermatitis, with a Supplemental New Drug Application (sNDA) submission expected in Q2 2026Announced expansion of its dermatology sales force and, separately, the initiation of a targeted Arcutis commercialization effort for primary care and pediatric health care providersProduced positive op

    2/25/26 4:00:00 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amwell® to Participate in Upcoming Investor Conference

    BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, today announced that Mark Hirschhorn, CFO and COO, will participate in the TD Cowen 46th Annual Health Care Conference, taking place in Boston on March 3, including a fireside chat at 3:10 p.m. ET. An audio webcast of the fireside chat will be available at investors.amwell.com. About Amwell Amwell offers payers and health systems a single, comprehensive, technology-enabled care platform. We use technology to provide patients with better access to more convenient, affordable and effective care. The Amwell platform includes sof

    2/24/26 5:00:00 PM ET
    $AMWL
    Real Estate

    $AHG
    $AMWL
    $ARAV
    $ARQT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Baird Jennifer A bought $987 worth of shares (4,200 units at $0.24), increasing direct ownership by 13% to 36,200 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    12/22/25 6:55:38 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Messinger Michael bought $5,098 worth of shares (14,500 units at $0.35), increasing direct ownership by 483% to 17,500 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    12/11/25 6:49:59 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Director Van Heel Kenneth bought $30,812 worth of shares (35,000 units at $0.88), increasing direct ownership by 243% to 49,400 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    8/28/25 5:28:58 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $AHG
    $AMWL
    $ARAV
    $ARQT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Van Heel Kenneth was granted 3,000 shares, increasing direct ownership by 61% to 7,940 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    2/10/26 4:58:51 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Director Neuman John was granted 3,000 shares, increasing direct ownership by 33% to 12,200 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    2/10/26 4:58:22 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Director Baird Jennifer A was granted 3,000 shares, increasing direct ownership by 83% to 6,620 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    2/10/26 4:57:09 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $AHG
    $AMWL
    $ARAV
    $ARQT
    SEC Filings

    View All

    SEC Form 144 filed by Arcutis Biotherapeutics Inc.

    144 - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

    3/2/26 6:21:36 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Arcutis Biotherapeutics Inc.

    144 - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

    3/2/26 5:59:41 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Arcutis Biotherapeutics Inc.

    144 - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

    3/2/26 5:25:46 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $AMWL
    $ARAV
    $ARQT
    Financials

    Live finance-specific insights

    View All

    Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Q4 2025 net product revenue for ZORYVE® (roflumilast) was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 2025Full year 2025 net product revenue for ZORYVE was $372.1 million, an increase of 123% over the prior yearReported positive topline data for the INTEGUMENT-INFANT Phase 2 trial of ZORYVE cream 0.05% in children ages 3 to 24 months with mild to moderate atopic dermatitis, with a Supplemental New Drug Application (sNDA) submission expected in Q2 2026Announced expansion of its dermatology sales force and, separately, the initiation of a targeted Arcutis commercialization effort for primary care and pediatric health care providersProduced positive op

    2/25/26 4:00:00 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amwell® Announces Results for Fourth Quarter and Full Year 2025

    BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, today announced financial results for the fourth quarter and full year ended December 31, 2025. The company's fourth quarter and full year 2025 earnings report can be viewed at investors.amwell.com. Amwell will host a conference call to discuss its financial results today at 5 p.m. ET. The call can be accessed via a live audio webcast at https://edge.media-server.com/mmc/p/7o2zjx2o/. A webcast replay will be available for approximately 90 days at investors.amwell.com. About Amwell Amwell offers payers and health systems a si

    2/12/26 4:05:00 PM ET
    $AMWL
    Real Estate

    Amwell® to report fourth quarter and full year 2025 operating results

    BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, will report fourth quarter and full year 2025 operating results after stock market trading hours on Thursday, Feb. 12. Following the distribution of the earnings alert via wire services, the Amwell management team will host a live conference call and webcast at 5 p.m. ET to review the company's operating results and provide a general business update. The full earnings report and the live audio webcast can be accessed by visiting the Investors section of the company's website. A webcast replay of the call will be available at

    2/5/26 4:05:00 PM ET
    $AMWL
    Real Estate

    $AHG
    $AMWL
    $ARAV
    $ARQT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Arcutis Biotherapeutics Inc.

    SC 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

    11/14/24 7:50:59 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Meihua International Medical Technologies Co. Ltd.

    SC 13G - Meihua International Medical Technologies Co., Ltd. (0001835615) (Subject)

    11/14/24 6:08:55 PM ET
    $MHUA
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by SeaStar Medical Holding Corporation

    SC 13G - SeaStar Medical Holding Corp (0001831868) (Subject)

    11/14/24 5:35:52 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $AHG
    $AMWL
    $ARAV
    $ARQT
    Leadership Updates

    Live Leadership Updates

    View All

    Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri

    WESTLAKE VILLAGE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Amit Munshi has been appointed to the Arcutis Board of Directors effective December 4, 2025, and announced the retirement of founder and long-serving Board member Bhaskar Chaudhuri, PhD. Dr. Chaudhuri will continue as a consultant for the Company. "As Arcutis looks to continue to grow in this next chapter, we are delighted to welcome Amit, an exceptional and visionary biopharmaceutical leader, to the Arcutis Board," said Frank Watanabe, president and chi

    12/8/25 4:00:00 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SeaStar Medical Announces Appointment of Michael Messinger as CFO

    DENVER, Nov. 17, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Michael Messinger, a seasoned healthcare executive with over 25 years of industry experience, has joined SeaStar Medical as Chief Financial Officer. "Mike brings to SeaStar Medical a breadth of financial expertise, operational discipline, and strategic healthcare experience that will be invaluable as we grow our commercial operations and prepare for additional commercial opportunities for our SCD therapy," stated Eric Schlorff, CE

    11/17/25 8:43:00 AM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer

    Co-Founder and former Chief Technical Officer of Arcutis Biotherapeutics brings extensive topical product development experience, including track record of translating science into commercially available therapies Dr. Osborne to guide expansion of QTORIN™ platform, including second QTORIN™ product candidate on track to be announced by year-end 2025 WAYNE, Pa., Sept. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella or "the Company"), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration

    9/3/25 7:30:00 AM ET
    $ARQT
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care